Travere Therapeutics (TVTX) Change in Accured Expenses (2011 - 2026)

Travere Therapeutics has reported Change in Accured Expenses for 16 years, with the latest figure at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 173.62% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (down 85.65% YoY), and the FY2025 full-year result was -$85000.0, up 99.52% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $1.9 million, down from $6.2 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $23.5 million in Q4 2023, with the low at -$24.8 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged $294352.9 across 5 years, with a median of -$242000.0 in 2023.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses soared 1768.18% — and 2024, when it tumbled 10337.39%.
• Travere Therapeutics' Change in Accured Expenses stood at -$1.4 million in 2022, then soared by 1768.18% to $23.5 million in 2023, then slumped by 95.71% to $1.0 million in 2024, then jumped by 518.51% to $6.2 million in 2025, then tumbled by 68.95% to $1.9 million in 2026.
• The last three Change in Accured Expenses figures came in at $1.9 million (Q1 2026), $6.2 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.